1Liang W, Wu X, Fang W, Zhao Y, Yang Y, et al. (2014) Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations. PLoS One 9:e85245.
2Mok T, Wu YL, Au JS, Zhou C, Zhang L, et al. (2010) Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer. J Thorac Oncol 5:1609-1615.
3Reck M, Mok T, Wolf J, Heigener D, Wu YL (2011) Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opin Drug Saf 10:147-157.
4Tammaro KA, Baldwin PD, Lundberg AS (2005) Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharm Pract 11:127-130.
5Kubota K, Nishiwaki Y, Tamura T, Nakagawa K, Matsui K, et al. (2008) Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 3:1439-1445.
6Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, et al. (2010) Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer. Anticancer Res 30:557-563.
7Nasrallah H, Bar-Sela G, Haim N (2012) Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer. Med Oncol 29:212-214.
8Nakagawa K, Kudoh S, Ohe Y, Johkoh T, Ando M, et al. (2012) Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 7:1296-1303.
9Ren S, Li Y, Li W, Zhao Z, Jin C, et al. (2012) Fatal asymmetric interstitial lung disease after erlotinib for lung cancer. Respiration 84:431-435.
10D'Alessandris QG, Pallini R (2013) Response to: "rare serious complications of erlotinib therapy". Acta Neurochir (Wien) 155:745.
11Atagi S, Katakami N, Yoshioka H, Fukuoka M, Kudoh S, et al. (2013) Nested case control study of proteomic biomarkers for interstitial lung disease in Japanese patients with non-small-cell lung cancer treated with erlotinib: a multicenter phase IV study (JO21661). Clin Lung Cancer 14:407-417.
12Qi WX, Sun YJ, Shen Z, Yao Y (2015) Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials. J Chemother 27:40-51.
13Shi L, Tang J, Tong L, Liu Z (2014) Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer 83:231-239.
14Fujita K, Hirose T, Kusumoto S, Sugiyama T, Shirai T, et al. (2014) High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer. Lung Cancer 86:113-114.
15Cohen MH, Johnson JR, Chen YF, Sridhara R, Pazdur R (2005) FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10:461-466.
16Johkoh T, Sakai F, Kusumoto M, Arakawa H, Harada R, et al. (2014) Association Between Baseline Pulmonary Status and Interstitial Lung Disease in Patients With Non-Small Cell Lung Cancer Treated With Erlotinib-A Cohort Study. Clin Lung Cancer 15:448-454.
17Kunkel J, Loddenkemper C, Grozdanovic Z, Schulze K, Schmittel A, et al. (2011) Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma. Pancreas 40:170-171.
18Yoneda KY, Hardin KA, Gandara DR, Shelton DK (2006) Interstitial lung disease associated with epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small-cell lung carcinoma. Clin Lung Cancer 8:S31-35.
19Tsubata Y, Hamada A, Sutani A, Isobe T (2012) Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient. J Cancer Res Ther 8:154-156.
20Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, et al. (2013) Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clin Pharmacokinet 52:593-609.
21Hamada A, Sasaki J, Saeki S, Iwamoto N, Inaba M, et al. (2012) Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non-small-cell lung cancer. Pharmacogenomics 13:615-624.
22Vahid B, Esmaili A (2007) Erlotinib-associated acute pneumonitis: report of two cases. Can Respir J 14:167-170.
23Higenbottam T, Kuwano K, Nemery B, Fujita Y (2004) Understanding the mechanisms of drug-associated interstitial lung disease. Br J Cancer 91:S31-37.
24Li X, Kamenecka TM, Cameron MD (2010) Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab Dispos 38:1238-1245.
25Lind JS, Smit EF, Grünberg K, Senan S, Lagerwaard FJ (2008) Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. J Thorac Oncol 3:1050-1053.
26Min JH, Lee HY, Lim H, Ahn MJ, Park K, et al. (2011) Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother Pharmacol 68:1099-1109.
27Onal C, Abali H, Koc Z, Kara S (2012) Radiation recall pneumonitis caused by erlotinib after palliative definitive radiotherapy. Onkologie 35:191-194.
28Taj A, Kanjwal S, Hammersley JR (2011) New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung. Am J Ther 18:e19-21.
29Del Castillo Y, Espinosa P, Bodí F, Alcega R, Muñoz E, et al. (2010) Interstitial lung disease associated to erlotinib treatment: a case report. Cases J 3:59.
30Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, et al. (2012) Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature. Lung Cancer 77:464-468.
31Boeck S, Hausmann A, Reibke R, Schulz C, Heinemann V (2007) Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer. Anticancer Drugs 18:1109-1111.
32Lai YC, Lin PC, Lai JI, Hsu SY, Kuo LC, et al. (2011) Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. Int J Clin Pharmacol Ther 49:461-466.
33Makris D, Scherpereel A, Copin MC, Colin G, Brun L, et al. (2007) Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 7:150.
34ter Heine R, van den Bosch RT, Schaefer-Prokop CM, Lankheet NA, Beijnen JH, et al. (2012) Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung Cancer 75:391-397.